Welcome to our dedicated page for DEVONIAN HEALTH GROUP news (Ticker: DVHGF), a resource for investors and traders seeking the latest updates and insights on DEVONIAN HEALTH GROUP stock.
Devonian Health Group Inc. reports developments as a clinical-stage biopharmaceutical company focused on therapies for fibro-inflammatory diseases. Company news centers on Thykamine™, including preclinical data in MASH and pulmonary fibrosis models, anti-inflammatory and anti-fibrotic research, intellectual-property filings, manufacturing controls and its radiodermatitis prevention program.
Recurring updates also cover Devonian's cosmeceutical activities, its Quebec extraction facility and Altius Healthcare Group LP, a commercialization subsidiary that sells licensed prescription pharmaceutical products in Canada. Corporate news includes financial results, board and management changes, shareholder meeting outcomes, stock-option grants and capital-structure actions such as its common-share consolidation.
Devonian Health (OTCQB: DVHGF) reported positive preclinical results for Thykamine in a bleomycin-induced pulmonary fibrosis mouse model on Feb 10, 2026. Thykamine, given orally at doses including 0.5 mg/kg, produced statistically significant reductions in lung wet weight, fibrosis (Ashcroft) and inflammation versus bleomycin controls.
Gene expression changes included downregulation of Fn1, Col1a1, Col3a1, Col6a1/3, Birc5, Ccl2, Cxcl2 and increased Mmp9 with reduced Mmp13, suggesting controlled matrix remodeling and antifibrotic activity. Pirfenidone at 220 mg/kg did not reach significance on physiological endpoints.
Devonian Health Group (OTCQB: DVHGF) appointed Dennis Turpin as Chief Financial Officer effective February 2, 2026; he will remain on the board and previously chaired the audit committee. The company granted Mr. Turpin 25,000 options vesting immediately at an $11.50 exercise price for 10 years.
The company corrected prior option disclosures: a pre-consolidation exercise price was revised from $0.18 to $0.19, then adjusted to $11.40 post-consolidation after a 1-for-60 share consolidation on January 22, 2026; option counts were rounded down per the plan.
Devonian Health Group (OTCQB: DVHGF; TSXV: GSD) announced a 1-for-60 share consolidation, approved by shareholders with 99.79% support, as part of preparations for a potential U.S. listing. The consolidation is subject to final TSXV acceptance and is expected to take effect at market open on or around January 22, 2026. Post-consolidation the company expects approximately 2,765,725 common shares outstanding (from 165,943,512 today), with no fractional shares issued and rounding to the nearest whole share. The OTCQB symbol will temporarily append a "D" for 20 business days after effectiveness. New CUSIP 251834883 and ISIN CA2518348834 will apply.
Devonian Health Group (OTCQB: DVHGF) announced on December 19, 2025 that its Board approved grants of stock options totaling 3,434,006 options. The grants consist of 2,948,056 options to directors and a consultant (including 2,798,056 to directors), 385,950 to employees as performance/retainer awards, and 100,000 to an R&D consultant.
The options are exercisable at $0.18 per share, expire 10 years from the grant date, and vest 25% on grant then 25% per year for three years.
Devonian Health Group (OTCQB: DVHGF) announced on December 4, 2025 the publication of a peer-reviewed article in Biomedicines titled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs." Researchers compared Thykamine™ with six widely prescribed anti-inflammatory drugs in an in vitro immune-activated cell model and reported that Thykamine™ inhibited MCP-1, MIP-1α and MIP-1β with greater potency than all comparators and suppressed RANTES comparable or superior to most agents tested. Effects occurred at lower concentrations and with no detectable cytotoxicity, suggesting a favorable tolerability profile and potential for further therapeutic development targeting chronic inflammatory and fibrotic conditions.
Devonian Health Group (OTCQB: DVHGF) reported fourth-quarter and fiscal 2025 results for the year ended July 31, 2025. Key metrics: Q4 distribution revenue $1.3M (down 87% YoY), FY distribution revenue $23.6M (up 22% YoY), Q4 net loss $0.375M ($0.003/share), and FY net loss $6.0M ($0.041/share). The FY loss included a $4.6M goodwill impairment and $0.2M IP impairment. R&D spending rose to $2.0M (up 55.8%) to support Thykamine pediatric phase 2/3 and preclinical work. The corporation is debt free after repaying $2.2M and held $7.0M cash at July 31, 2025. Pierre Labbé was appointed to the board.
Devonian Health Group (OTCQB: DVHGF), a clinical-stage biopharmaceutical company, provided updates on multiple fronts. The company reported significant progress with its flagship drug Thykamine™, validating batch-to-batch consistency through advanced analytical techniques and advancing pre-clinical programs in MASH and pulmonary fibrosis, with data expected in fall 2025.
The company is developing oral formulations for Thykamine™ and received positive U.S. dermatologist survey results for pediatric atopic dermatitis applications. Additionally, Devonian announced the upcoming termination of its Pantoprazole Magnesium distribution agreement in April 2026, which represented 10.6% of FY2024 revenues and 4.2% of revenue for the nine months ended April 2025.
The company also corrected details of its recent private placement, noting total gross proceeds of $2.36 million through the issuance of 15.75 million units at $0.15 per unit, each including one share and one warrant exercisable at $0.20 for 24 months.
Devonian Health Group (OTCQB: DVHGF), a clinical-stage company focused on inflammatory disease solutions, has completed a non-brokered private placement raising $2.27 million in gross proceeds. The offering consisted of 15,153,332 units priced at $0.15 per unit, with each unit comprising one subordinate voting share and one warrant.
Each warrant allows holders to purchase one share at $0.20 within a 24-month period. The funds will support working capital needs, corporate overhead, and R&D activities. The securities have a four-month restricted hold period ending December 8, 2025.
Devonian Health Group (OTCQB:DVHGF) reported its Q3 2025 financial results, with revenue increasing 36% year-over-year to $7.36 million. The company recorded a net loss of $0.032 per share, primarily due to a $4.84 million non-cash impairment loss related to the expiration of their DEXLANSOPRAZOLE distribution agreement.
The quarter saw significant management changes with Dr. Andre Boulet appointed as CEO and Luc Gregoire as Executive Vice-President Strategy. The company completed preclinical studies for Thykamine™, exploring new applications in inflammatory diseases, including MASH and fibrosis.